165 related articles for article (PubMed ID: 37565583)
1. Potential drug repurposing of ruxolitinib to inhibit the JAK/STAT pathway for the treatment of patients with epithelial ovarian cancer.
Yunianto I; Currie M; Chitcholtan K; Sykes P
J Obstet Gynaecol Res; 2023 Nov; 49(11):2563-2574. PubMed ID: 37565583
[TBL] [Abstract][Full Text] [Related]
2. Quercetin as a JAK-STAT inhibitor: a potential role in solid tumors and neurodegenerative diseases.
Zalpoor H; Nabi-Afjadi M; Forghaniesfidvajani R; Tavakol C; Farahighasreaboonasr F; Pakizeh F; Dana VG; Seif F
Cell Mol Biol Lett; 2022 Jul; 27(1):60. PubMed ID: 35883021
[TBL] [Abstract][Full Text] [Related]
3. JAK-STAT inhibition reduces endothelial prothrombotic activation and leukocyte-endothelial proadhesive interactions.
Beckman JD; DaSilva A; Aronovich E; Nguyen A; Nguyen J; Hargis G; Reynolds D; Vercellotti GM; Betts B; Wood DK
J Thromb Haemost; 2023 May; 21(5):1366-1380. PubMed ID: 36738826
[TBL] [Abstract][Full Text] [Related]
4. Impact of heat stress on prolactin-mediated ovarian JAK-STAT signaling in postpubertal gilts.
Roach CM; Bidne KL; Romoser MR; Ross JW; Baumgard LH; Keating AF
J Anim Sci; 2022 Jul; 100(7):. PubMed ID: 35772766
[TBL] [Abstract][Full Text] [Related]
5. Targeting the JAK-STAT pathway in autoimmune diseases and cancers: A focus on molecular mechanisms and therapeutic potential.
Tzeng HT; Chyuan IT; Lai JH
Biochem Pharmacol; 2021 Nov; 193():114760. PubMed ID: 34492272
[TBL] [Abstract][Full Text] [Related]
6. Targeting the JAK/STAT Pathway in T Cell Lymphoproliferative Disorders.
Shouse G; Nikolaenko L
Curr Hematol Malig Rep; 2019 Dec; 14(6):570-576. PubMed ID: 31741284
[TBL] [Abstract][Full Text] [Related]
7. Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma.
Toh TB; Lim JJ; Hooi L; Rashid MBMA; Chow EK
J Hepatol; 2020 Jan; 72(1):104-118. PubMed ID: 31541681
[TBL] [Abstract][Full Text] [Related]
8. [Research Advances of JAK/STAT Signaling Pathway in Lung Cancer].
Yang X; Tang Z; Zhang P; Zhang L
Zhongguo Fei Ai Za Zhi; 2019 Jan; 22(1):45-51. PubMed ID: 30674393
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis.
Calabrese L; Chiricozzi A; De Simone C; Fossati B; D'Amore A; Peris K
Expert Opin Drug Metab Toxicol; 2022 May; 18(5):347-355. PubMed ID: 35796377
[TBL] [Abstract][Full Text] [Related]
10. Targeting the JAK/STAT pathway in solid tumors.
Qureshy Z; Johnson DE; Grandis JR
J Cancer Metastasis Treat; 2020; 6():. PubMed ID: 33521321
[TBL] [Abstract][Full Text] [Related]
11. JAK-STAT pathway inhibitors in dermatology.
Miot HA; Criado PR; de Castro CCS; Ianhez M; Talhari C; Ramos PM
An Bras Dermatol; 2023; 98(5):656-677. PubMed ID: 37230920
[TBL] [Abstract][Full Text] [Related]
12. Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms.
Gurska LM; Okabe R; Schurer A; Tong MM; Soto M; Choi D; Ames K; Glushakow-Smith S; Montoya A; Tein E; Miles LA; Cheng H; Hankey-Giblin P; Levine RL; Goel S; Halmos B; Gritsman K
Clin Cancer Res; 2023 Mar; 29(5):943-956. PubMed ID: 36537918
[TBL] [Abstract][Full Text] [Related]
13. Exploring the JAK/STAT Signaling Pathway in Hepatocellular Carcinoma: Unraveling Signaling Complexity and Therapeutic Implications.
Park H; Lee S; Lee J; Moon H; Ro SW
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762066
[TBL] [Abstract][Full Text] [Related]
14. Impact of JAK/STAT inhibitors on human monocyte-derived-macrophages stimulated by cigarette smoke extract and lipopolysaccharide.
Verres Y; da Silva CO; Aljebawi B; Bodin A; Barreto E; Lagente V; Victoni T
Clin Exp Pharmacol Physiol; 2022 Nov; 49(11):1187-1196. PubMed ID: 35876719
[TBL] [Abstract][Full Text] [Related]
15. Janus Kinase Inhibitors: A Review of Their Application in the Vitiligo.
Niu C; Xie H; Aisa HA
Mini Rev Med Chem; 2021; 21(20):3203-3218. PubMed ID: 33823765
[TBL] [Abstract][Full Text] [Related]
16. JAK/STAT of all trades: linking inflammation with cancer development, tumor progression and therapy resistance.
Sabaawy HE; Ryan BM; Khiabanian H; Pine SR
Carcinogenesis; 2021 Dec; 42(12):1411-1419. PubMed ID: 34415330
[TBL] [Abstract][Full Text] [Related]
17. Merkel cell polyomavirus-negative Merkel cell carcinoma is associated with JAK-STAT and MEK-ERK pathway activation.
Iwasaki T; Hayashi K; Matsushita M; Nonaka D; Kohashi K; Kuwamoto S; Umekita Y; Oda Y
Cancer Sci; 2022 Jan; 113(1):251-260. PubMed ID: 34724284
[TBL] [Abstract][Full Text] [Related]
18. Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia.
Zhang M; Mathews Griner LA; Ju W; Duveau DY; Guha R; Petrus MN; Wen B; Maeda M; Shinn P; Ferrer M; Conlon KD; Bamford RN; O'Shea JJ; Thomas CJ; Waldmann TA
Proc Natl Acad Sci U S A; 2015 Oct; 112(40):12480-5. PubMed ID: 26396258
[TBL] [Abstract][Full Text] [Related]
19. JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review.
Huang IH; Chung WH; Wu PC; Chen CB
Front Immunol; 2022; 13():1068260. PubMed ID: 36569854
[TBL] [Abstract][Full Text] [Related]
20. Targeting the JAK/STAT Signaling Pathway for Breast Cancer.
Shao F; Pang X; Baeg GH
Curr Med Chem; 2021; 28(25):5137-5151. PubMed ID: 33290193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
